Press releases
- All
2021
May 6, 2021
Regulatory
Report from the annual general meeting of IRLAB Therapeutics AB
May 6, 2021
Regulatory
IRLAB interim report January – March 2021
May 5, 2021
IRLAB publishes recorded speech and company presentation prior to digital AGM
April 15, 2021
Regulatory
IRLAB’s annual report for 2020 is now available on the company’s website
April 8, 2021
IRLAB’s nomination committee proposes Martin Nicklasson as new board member and provides their proposal
March 25, 2021
IRLAB’s drug candidate mesdopetam’s mechanism of action receives confirmation by independent scientists
March 9, 2021
First European patients dosed in IRLAB’s Phase IIb/III mesdopetam study
February 24, 2021
Regulatory
IRLAB’s Year-end report January 1 – December 31, 2020
January 29, 2021
Regulatory
IRLAB announces change in share capital and number of shares following registered directed share issue
January 12, 2021
IRLAB presents application of deep learning on multidimensional CNS drug efficacy data
January 11, 2021
IRLAB presents new data indicating that mesdopetam could prevent dyskinesia in Parkinson’s Disease
2020
December 18, 2020
Regulatory
IRLAB Therapeutics carries out a directed share issue in the amount of SEK 130,000,000
December 8, 2020
IRLAB strengthens patent protection for Phase IIb/III drug candidate mesdopetam
November 4, 2020
IRLAB starts Phase IIb/III study with mesdopetam in the US
October 30, 2020
Regulatory
Nomination committee in IRLAB appointed ahead of annual general meeting 2021
October 1, 2020
Regulatory
IRLAB’s mesdopetam IND accepted by the US FDA
September 30, 2020
IRLAB’s shares are now traded on Nasdaq Stockholm Main Market
September 25, 2020
Regulatory
IRLAB publishes prospectus in connection with its listing on Nasdaq Stockholm Main Market
September 23, 2020
Regulatory
IRLAB Therapeutics has been approved for listing on Nasdaq Stockholm Main Market
September 10, 2020
IRLAB’s drug candidate pirepemat featured on cover of top-tier journal JPET
August 3, 2020
IRLAB’s IRL752 is proposed pirepemat as a unique INN by WHO
July 9, 2020
IRLAB’s clinical drug candidate IRL752 published in JPET
June 24, 2020
IRLAB’s mesdopetam featured on cover of top-tier publication JPET
June 4, 2020
IRLAB’s Phase IIb/III study in Parkinson’s disease to target Good ON
May 7, 2020
Regulatory
Report from the Annual General Meeting of IRLAB Therapeutics AB
May 6, 2020
IRLAB’s clinical drug candidate mesdopetam published in JPET
April 7, 2020
Regulatory
IRLAB publishes the annual report for 2019
March 23, 2020
IRLAB’s Phase IIa study with IRL752 is published in Movement Disorders
February 27, 2020
IRLAB’s rights issue oversubscribed
February 7, 2020
Regulatory
IRLAB publishes prospectus relating to the rights issue
February 4, 2020
IRLAB’s IRL790 receives new name ‘mesdopetam’
2019
December 12, 2019
Regulatory
IRLAB has carried out a directed issue of SEK 70 million and resolves on a rights issue of approximately SEK 145 million
December 12, 2019
Regulatory
IRLAB intends to make a capital raise of approximately SEK 215 million
November 6, 2019
IRLAB’s drug candidates IRL942 and IRL1009 have been granted patents in the US and Europe
October 21, 2019
IRLAB is presenting at the Society for Neuroscience 2019 Neuroscience conference
October 17, 2019
Regulatory
Nomination committee in IRLAB appointed
September 26, 2019
IRLAB’s IRL790 is proposed a unique INN by WHO
September 23, 2019
IRLAB presents at the 2019 International Congress of Parkinson’s Disease and Movement Disorders
August 28, 2019
IRLAB to advance clinical development of IRL790 in LIDs based on in-depth analysis of positive Phase IIa results
July 15, 2019
Regulatory
IRLAB reports top line results from Phase IIa study with IRL790
May 28, 2019
IRLAB and research consortium awarded MSEK 2.9 Vinnova grant
May 27, 2019
Today, May 27, is the last day of trading in IRLAB’s share before share split
May 17, 2019
Regulatory
IRLAB announces share split
April 25, 2019
Regulatory
IRLAB – Resolutions at Annual General Meeting 2019
April 3, 2019
Regulatory
IRLAB Therapeutics AB publishes annual report for 2018
March 14, 2019
IRLAB adds sites to Phase II study with IRL790 and passes DSMB’s second safety review
2018
December 18, 2018
IRLAB provides update on drug candidate IRL790’s clinical program
December 6, 2018
Nature’s npj Parkinson’s Disease publishes clinical study with IRLAB’s drug candidate IRL790
November 22, 2018
A new patent application for IRLAB’s drug candidate IRL752 has been published by World Intellectual Property Organization, WIPO
October 30, 2018
IRLAB provides in-depth information on results from successful Phase IIa study with IRL752 in Parkinson’s disease
September 26, 2018
IRLAB presents ISP at the CNS and Neurodegenerative Targets conference in Boston
September 20, 2018
Regulatory
Nomination committee appointed in IRLAB
September 19, 2018
Regulatory
IRLAB nominates two new candidate drugs and updates the pipeline
September 11, 2018
IRLAB Receives Notice of Allowance for U.S. Patent
August 30, 2018
IRLAB reports promising efficacy data from Phase IIa-study with IRL752
August 30, 2018
Regulatory
IRLAB reports promising efficacy data from Phase IIa-study with IRL752
August 29, 2018
IRLAB report for Q2 2018
June 29, 2018
Regulatory
IRLAB reports top-line results from Phase IIa study with IRL752
May 23, 2018
Regulatory
IRLAB Therapeutics has raised SEK 138.6 million in a directed share issue to top tier investors in the US and Sweden
May 17, 2018
Regulatory
IRLAB prepares for listing on the Nasdaq Stockholm main market
May 16, 2018
Regulatory
IRLAB – Resolutions at Annual General Meeting 2018
April 13, 2018
Summoning to Annual General Meeting
March 12, 2018
International attention on IRLAB’s discovery program
March 12, 2018
International attention on IRLAB’s discovery platform
February 23, 2018
IRLAB featured in SwedenBIO press release
January 31, 2018
IRLAB update on clinical Phase II pipeline – IRL752 and IRL790
2017
November 15, 2017
Regulatory
IRLAB receives MHRA approval to conduct Phase II trials with IRL790 in Britain
October 5, 2017
Regulatory
IRLAB receives approval from the Finnish MPA (Fimea)
October 4, 2017
IRLAB starts Phase II study with IRL752 for the treatment of Parkinson’s disease dementia
September 20, 2017
Regulatory
Nomination committee appointed in IRLAB
August 25, 2017
Regulatory
IRLAB receives approval to initiate Phase II trials with IRL752
August 17, 2017
Regulatory
IRLAB signs agreement with TCTC to conduct Phase-2 study with IRL790
May 16, 2017
Regulatory
IRLAB Therapeutics delårsrapport jan-mars 2017
May 15, 2017
IRLAB announces positive results from Phase Ib study with IRL790
April 24, 2017
IRLAB strengthens Board of Directors with leading competences
April 10, 2017
Annual Report for 2016 published
April 10, 2017
IRLAB Therapeutics AB summons its shareholders to the Annual General Meeting in Gothenburg on May 16, 2017
April 10, 2017
Regulatory
IRLAB Therapeutics AB (publ) publicerar årsredovisning för 2016
February 28, 2017
First day of trading of shares for IRLAB Therapeutics AB (publ.) at Nasdaq First North Premier
February 27, 2017
Regulatory
IRLAB Therapeutics AB (publ) Bokslutskommuniké för 2016
February 14, 2017
IRLAB Therapeutics announces outcome of new share issue – first day of trade planned for February 28th
January 24, 2017
IRL’s drug discovery platform, the Integrative Screening Process (ISP), and an application, has been published in ACS Chemical Neuroscience
2016
October 13, 2016
IRL receives MPA approval to conduct a 4 week Phase Ib clinical study with IRL790 in patients with Parkinsons disease
February 3, 2016
IRL receives MPA approval and initiates Phase I trials with IRL752, its second compound reaching clinical development
2015
December 14, 2015
IRL receives SEK 4.98 million from Vinnova for Phase I studies with IRL790
October 30, 2015
IRL receives MPA approval to conduct Phase I trials with IRL790, a novel treatment for complications in Parkinson’s disease
October 9, 2015
IRL scientists lead investigation of long term clinical effects of widely prescribed medications in neurodegenerative disorders
May 25, 2015
IRL files new patent application
May 25, 2015
Highly experienced pharma executives join IRL’s Board of Directors
2014
October 21, 2014
IRL secures additional financing
June 23, 2014
IRL receives SEK 3.8 million from VINNOVA